anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a Chinese herbal medicine composition used for treating dog eczema. The Chinese herbal medicine composition possesses relatively excellent therapeutic effects on dog eczema symptoms caused by poor breeding management, malnutrition and the like. The Chinese herbal medicine composition comprises following ingredients: Chinese honeylocust fruit, radix stemonae, radix sophorae flavescentis, radix scutellariae and mint. The Chinese herbal medicine composition is prepared by following steps: the ingredients above are boiled with water, wherein the water amount is 8 times of the amount of the ingredients; about 30min later, the mixture is cooled until the mixture is warm. Administration is that: affected skin is washed or subjected to hydropathic compress by the warm Chinese herbal medicine composition over and over again, and two times a day. Effectiveness will be realized in 2 to 3 days. The Chinese herbal medicine composition is prepared according to a traditional Chinese medicine formula, is capable of curing dog eczema symptoms effectively, and possesses no toxic or side effect.
Wu Dang 13 form postures will be performed. Initially, each posture will be performed 3 times then progressively increase to more according to the patient's discomfort.
The invention belongs to the technical field of enteric-coated capsules, and especially relates to hollow hard capsules with a sweet taste. The capsules are prepared from gelatin, starch, cellulose, and glycerol. The capsules also comprise, by weight, 10-30 parts of auxiliary materials and 1-5 parts of a sweetening agent. According to the invention, traditional Chinese medicines mint with a sweet and cooling taste and licorice root, and a proper amount of a sweetening agent are adopted, such that the produced hard hollow capsules are provided with a good taste. The capsules can be used for coating children-use medicines with bitter or irritating tastes. With the capsules, children medication pains can be greatly relieved. The capsules are also suitable for various populations. According to the invention, preparation raw materials and medicine materials have no toxic or side effects. The process is simple and reasonable, the cost is low, and the capsules are safe and reliable. According to the invention, no added device is needed, and production can be carried out by pharmaceutical factories or capsule production factories. The capsules are suitable for large-scale productions of pharmacy-related enterprises, and have good market prospect.
PURPOSE: Provided is a whitening cosmetics which contains natural extracts and is excellent in improvement of discoloration on the face, freckles, skin pigmentation disorders, etc. CONSTITUTION: The cosmetic composition is characterized by comprising at least one kind of extract selected from Daphne genkwa Sieb. Et Zucc. and peach seeds, wherein the Daphne genkwa Sieb. Et Zucc. and the peach seeds are sequentially extracted by using a first extraction solvent, such as ethanol, methanol, propanol, butanol, amylalcohol, isopropanol, acetone, ethylmethylketone, et.c, then by using a second extraction solvent , such as ethylacetate, dimethylether, benzene, dichloromethane, chloroform, etc.
Evaluate the basic 3-marker multi-biomarker test (MBT) signature in 150 participants across three African sites. This will be used to lock down the final MBT signature to be used in the next phase of testing.
The invention discloses a medicine for preventing and treating infectious rhinitis of chicken. The traditional Chinese medicine is prepared from the following traditional Chinese medicines in a certain proportion: flos Magnoliae, herba Houttuyniae, radix Angelicae Dahuricae, herba Menthae, radix Curcumae, radix Adenophorae, rhizoma anemarrhenae, Scutellariae radix, fructus Xanthii, radix aucklandiae, Alumen, Glycyrrhrizae radix, radix Saposhnikoviae, radix et rhizoma Rhei, and fructus Gardeniae. Pulverizing the above materials, grinding, mixing, and stirring. In clinical application, the medicine is soaked in boiling water for 30-60 minutes, so that the effective components of the medicine are fully dissolved and separated out, the absorption in the body of a sick chicken is facilitated, and meanwhile, a small amount of sugar and Vc auxiliary treatment medicines are added, so that the medicine effect can be improved. The medicine has high clinical cure rate, no adverse reaction, no medicine residue and no hidden danger of drug resistance. The invention has the advantages of easily obtained medicinal materials, simple preparation method, exact curative effect and convenient use, and can be widely applied to the chicken industry.
Disgust as a primary emotion has evolved to protect our lives by driving dirt and disease avoidance behaviors and motivating for cleaning and hygienic behaviors. In recent years, many studies have focused on the role of disgust in psychiatric disorders such as anxiety disorders, eating disorders, body dysmorphic disorders, and phobias. Nowadays, we have robust evidence of the correlation between disgust and the etiology and treatment of OCD symptoms, particularly the contamination subtype. The principal explanation for the insufficient treatment effect of ERP is that disgust is resistant to extinction.

Since evaluative conditioning is one of the main sources of disgust feeling, the same process may effectively reduce disgust. The present trial will try to pair contamination-related pictures that are disgust-eliciting with positive, pleasant pictures in order to modify their disgust valence. We also will administer this EC training plus to OFC cathodal tDCS to see if the EC effect becomes more significant than EC alone.
Patients undergo IMRT 5 days a week over 5 weeks. Patients undergo PET scan, CT scan, MRI, and blood sample collection throughout the study.
Bipolar disorder (BD) is a chronic psychiatric condition characterized by large episodic changes in mood and energy. Recently, BD has been proposed to be conceptualized as chronic cyclical mood instability, as opposed to the traditional view of alternating discrete episodes with stable periods in-between. Recognizing this mood instability may improve care and call for high-frequency measures coupled with advanced statistical models. To uncover empirically derived mood states, a multilevel hidden Markov model (HMM) was applied to 4-month ecological momentary assessment data in 20 patients with BD, yielding ∼9,820 assessments in total. Ecological momentary assessment data comprised self-report questionnaires (5 × daily) measuring manic and depressive constructs. Manic and depressive symptoms were also assessed weekly using the Altman Self-Rating Mania Scale and the Quick Inventory for Depressive Symptomatology Self-Report. Alignment between HMM-uncovered momentary mood states and weekly questionnaires was assessed with a multilevel linear model. HMM uncovered four mood states: neutral, elevated, mixed, and lowered, which aligned with weekly symptom scores. On average, patients remained < 25 hr in one state. In almost half of the patients, mood instability was observed. Switching between mood states, three patterns were identified: patients switching predominantly between (a) neutral and lowered states, (b) neutral and elevated states, and (c) mixed, elevated, and lowered states. In all, elevated and lowered mood states were interspersed by mixed states. The results indicate that chronic mood instability is a key feature of BD, even in "relatively" euthymic periods. This should be considered in theoretical and clinical conceptualizations of the disorder. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
The experimental group will receive thumb orthosis at night and daytime use for 3 to 4 hours during Activities of Daily Living that included the thumb MCP for three months. In addition to a classic home exercise program and a proprioceptive home exercises program divided in three phases.
BACKGROUND: The incidence of healthcare-associated infections, particularly injection-related infections, can increase patient comorbidities even in countries with adequate medical resources. Although there are clear guidelines for injection practices to prevent infections, their application in clinical settings is insufficient. Therefore, the objective of this study was to identify factors affecting injection practices associated with reduced infections by conducting surveys targeting practicing healthcare providers involved in administering injections at each healthcare organization and performing data analysis.
METHODS: We administered a survey to healthcare providers responsible for injection practices at each healthcare organization that included items related to infection-safe injection practice guidelines. All survey questions were reviewed by an expert panel of infectious disease and infection control nurses. Survey contents were subjected to exploratory factor analysis (EFA), confirmatory factor analysis, and multivariable robust regression tests to determine the impact of each factor and their correlations.
RESULTS: A total of 842 questionnaires were analyzed. Each questionnaire was classified into four factors: reuse and contamination, compliance with aseptic technique, exchange of infusion set, and use of multidose vials. Nurses with higher careers showed more compliance. Education within one year and awareness of each item of the questionnaire had positive associations with proper injection practice.
CONCLUSIONS: Education is thought to be the most important factor in good injection practices that could reduce infections. Relevant knowledge through timely training is expected to have a positive impact on performance and compliance related to safe injections.
The placebo will be provided in the same unmarked plain packages and contain the same constituents, but without flax (control packages contain oat fiber and milk). For 180 days (6 months) participants will consume 2 servings of 330 ml of placebo beverage (i.e. normal fiber beverage; control) per day.
All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
The primary aim is to assess the inter-patient correlation between SE results and outdoor air pollution levels in patients matched for clinical, coronary anatomy (if available) and resting functional features. Secondary aim is to assess the effects of air quality and cumulative medical radiation exposure in prognostic modeling using traditional risk factors and SE results. All patients enrolled in projects 1 to 4 have information on house residency and work place in the data bank. The air epidemiology unit will obtain same day local air quality data from publicly available data sets from regional authority of environmental protection. For each patient and each test of the same patient, the values of 2 particulate and 4 gaseous pollutants will be collected when available. Data on medical radiation exposure will also be systematically collected. Of the 2 430 tests recruited in protocol 1, at least 600 will have access to geo-referenced air quality data.
To construct and verify an easy-to-use nomogram for predicting the risk of infectious diseases in pediatric kidney transplant recipients. Clinical data of hospitalized pediatric kidney transplant recipients were retrospectively analyzed. Meaningful variables identified from the multivariate stepwise logistic regression analysis were used to construct the nomogram. Internal validation was performed using Bootstrap resampling 1,000 times. The nomogram was evaluated using calibration, decision and receiver operating characteristic (ROC) curves. A total of 297 pediatric kidney transplant recipients were included (164 infected, 133 non-infected). Multivariate stepwise regression analysis identified white blood cell count (WBC), lymphocyte to monocyte ratio (MLR), platelet to neutrophil ratio (PNR), red cell distribution width-standard deviation (RDW-SD), and albumin (ALB) as significant predictors of postoperative infection. The nomogram, based on the five indicators, showed strong discrimination ability (AUC = 0.756; 95% CI [0.702-0.811]), with a sensitivity of 88.0% and a specificity of 54.3%. The calibration curve and decision curve further demonstrated good consistency and clinical practicality between the predicted and actual values. WBC, MLR, PNR, RDW-SD, and ALB are effective indicators for predicting postoperative infection in pediatric kidney transplant recipients. The nomogram constructed from these indicators can effectively predict and evaluate the early risk of infection in these patients.
A novel TNF-preparation with high cytolytic activity is disclosed. The TNF preparation includes modified forms of tumor necrosis factor associated with the surface of liposomes of small diameter (between 0.02-0.05  mu m) known as SUV's. The tumor necrosis factor molecule is modified at up to 3 amino residues per trimer with nearly complete retention ( SIMILAR 80-95 %) of biological activity. The modified TNF amino residues are modified to include long chain fatty acids via TNF lysyl side chains and/or N-terminal amino groups. The disclosed modified TNF molecules provide a highly efficient method for preparing liposome-associated TNF complexes in either standard MLVs or SUVs having enhanced in vivo stability. The binding of said modified TNF molecules to the surface of small unilamellar vesicles is with up to 100 % efficiency. Pharmacologically acceptable preparations of modified TNF for the particular treatment of TNF-responsive tumors are also provided. Methods of preparing liposome associated-lipophilic TNF molecules are provided. The liposomes of the present invention are decribed as small unilamellar vesicles (SUV). The liposomes of the present invention feature particularly small diameters in the range of 0.02 - 0.05  mu m in diameter. Highly efficient methods of preparing stable, surface-associated protein liposome complexes having enhanced stability in vivo are also provided.
This study will support two avenues of research, pharmacokinetics (PK) of drugs used to treat tuberculosis and resistance to those drugs that has been developed by the pathogen. Given the high inter-individual variability in TB drug exposure, therapeutic drug monitoring would be of value to adjust the drug dose in TB patients in order to improve clinical outcome and minimize toxicity. It is not practiced in most settings for reasons associated with costs but also because blood collection is an invasive procedure. Sputum on the other hand is often produced spontaneously and discarded as waste. Drug levels can be measured in sputum just as in plasma. Here we will test the hypothesis that sputum drug levels are predictive of drug concentrations in plasma and/or in specific lesion compartments such as the caseum of open cavities. We will also characterize the exposure of standard 1st and 2nd line TB drugs at one of the sites of infection, since sputum is in direct contact with cavity caseum. The subjects will contribute three or more sputum samples spontaneously produced over at least two days and four blood samples following drug administration on two different days (8 blood samples total). The data will be analyzed using population PK modeling approaches to generate concentration-time profiles and 24-hour area under the curve (AUC) of each study drug in sputum. Correlations between these values, plasma and lesion AUCs will be examined. We will draw from a recently completed TB lesion pharmacokinetic study (www.ClinicalTrials.gov #NCT00816426) to seek correlations between drug exposure in sputum and in pulmonary lesions. In addition to drug concentrations, sputum will be cultured by standard methods to isolate Mycobacterium tuberculosis (Mtb), determine the drug resistance profile, and be saved for testing a second generation of the Xpert TB XDR assay.
The investigators plan to conduct 12 sessions of intervention, one hour per session, 2 sessions per week, for a total of 6 weeks. Participants will receive interventions in their home via online meetings with a certified occupational therapist. The training will be related to functional tasks in daily life. In addition, the investigators will guide participants to use self-management skills in their daily routines. Participants will receive booklets to conduct their self-practice and exercise for 30 minutes per session, two sessions per week, for a total of 6 weeks.
Participants received CMB305 treatment in combination with 1200 mg/day atezolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 2 years. CMB305 treatment consisted of 2 doses of LV305 administered intradermally (ID) on Days 0 and 14 followed every 2 weeks with alternating doses of G305 administered intramuscularly (IM) and LV305. LV305 was administered at a dose of 1×10\^10 vector genomes and G305 at a dose of 5 mcg glucopyranosyl lipid A stable emulsion mixed with 250 mcg of NY ESO-1 protein.
Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
PURPOSE:To prepare the titled globulin, easily in high yield, by dissolving a precipitate formed from blood plasma in a specific stabilizer, heating the solution, removing the contaminant protein component such as fibrinogen, etc., and freeze- drying the purified product. CONSTITUTION:The precipitate (cryoprecipitate) formed by the freezing and melting of blood plasma is dissolved in a stabilizer of the coagulation factor VIII(e.g. a neutra aqueous solution containing at least one compound selected from water-soluble amino acids such as glycine, lysine, alanine, glutamine, etc., sugars such as sucrose, glucose, mannitol, etc., and neutral salts such as NaCl, KCl, etc.). The solution is heated at 50-60 deg.C for 1-30min, the contaminant proteins such as fibrinogen, etc. are removed, and the purified product is freeze-dried to obtain a high-purity antihemophilic globulin. The operations other than the freeze-drying are carried out in an opened system or a closed system using a specific blood bag system.
AIM: To investigate the corneal central and limbal thickness in cornea scar patients using high-resolution anterior segment optical coherence tomography (AS-OCT) and to determine the changes in the limbal region due to the corneal scar. Also, to evaluate tear film parameters in scar patients.
METHODS: Thirty patients with central corneal scar and 30 control subjects. The control subjects were healthy individuals who came to our clinic for routine ophthalmological examination. They were enrolled in this matched case-control study. Central epithelial thickness (ET), stromal thickness (ST), limbal epithelial thickness (LET), and limbal stromal thickness (LST) were analyzed using high-resolution AS-OCT. For evaluation of the ocular surface, the following techniques were used: tear break-up time (BUT) employing standard sterile strips of fluorescein sodium, Schirmer test-I (SCH), and the Ocular Surface Disease Index (OSDI) Questionnaire.
RESULTS: The mean central ET of the patient group was 51.5 ± 12.4 µm, while the mean central ET of the control group was 59.2 ± 9.0 µm. There was a statistically significant difference between patients and controls (p = 0.008). The mean LST of the patients was 747.9 ± 115.7 µm, and the mean LST of the controls was 726.3 ± 79.7 µm. There was a statistically significant difference between patients and controls according to BUT (p = 0.009) and SCH (p = 0.04). However, there was no significant difference between OSDI results of patients and controls (p = 0.08).
CONCLUSION: Corneal monitoring with high-resolution AS-OCT is a simple, noninvasive, useful technique for corneal scar patients. Cornea scars cause decreased ET. This result could be associated with lower tear film parameters in scar patients. The scar length is associated with higher intraocular pressure (IOP) values. Decreased LET and increased LST were detected in scar patients.
Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 16 sessions (20-minutes per each 60-minute treatment session) over the course of 8 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
These are antagonists of interleukin-6, characterised in that they consist of soluble forms of the receptor .alpha. of human IL- 6 (shIL-6R.alpha.) containing one or more mutation in the gp 130 binding interface. In a preferred embodiment, the mutations are present in a position chosen from the group comprising Ala 228, Asn 230, His 280 and Asp 281. These antagonists can be used as agents capable of preventing and treating diseases caused by abnormal IL-6 activity. Figure 4 shows the antagonist activity of the mutant Ala228Asp/Asn 230Asp/His280Ser/Asp281Val in comparison with the agonist properties of wild type shIL-6R.alpha.. This antagonist can be used for preparation of drugs for the prevention, control and treatment of diseases caused by abnormal IL-6 bioactivity. (Fig.4)
Patients suffering from chronic fatigue syndrome (CFS) or post-COVID syndrome (PCS) exhibit a reduced physiological performance capability. Impaired mitochondrial function and morphology may play a pivotal role. Thus, we aimed to measure the muscle mitochondrial oxidative phosphorylation (OXPHOS) capacity and assess mitochondrial morphology in CFS and PCS patients in comparison to healthy controls (HCs). Mitochondrial OXPHOS capacity was measured in permeabilized muscle fibers using high-resolution respirometry. Mitochondrial morphology (subsarcolemmal/intermyofibrillar mitochondrial form/cristae/diameter/circumference/area) and content (number and proportion/cell) were assessed via electron microscopy. Analyses included differences in OXPHOS between HC, CFS, and PCS, whereas comparisons in morphology/content were made for CFS vs. PCS. OXPHOS capacity of complex I, which was reduced in PCS compared to HC. While the subsarcolemmal area, volume/cell, diameter, and perimeter were higher in PCS vs. CFS, no difference was observed for these variables in intermyofibrillar mitochondria. Both the intermyofibrillar and subsarcolemmal cristae integrity was higher in PCS compared to CFS. Both CFS and PCS exhibit increased fatigue and impaired mitochondrial function, but the progressed pathological morphological changes in CFS suggest structural changes due to prolonged inactivity or unknown molecular causes. Instead, the significantly lower complex I activity in PCS suggests probably direct virus-induced alterations.